To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04730544
Title Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)
Acronym NIPISAFE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GERCOR - Multidisciplinary Oncology Cooperative Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Institut Sainte Catherine Avignon France Details
CHU Jean Minjoz Besançon France Details
CHU Morvan Brest France Details
Hôpital Henri Mondor Créteil France Details
Centre Georges François Leclerc Dijon France Details
Clinique Victor Hugo-Centre jean Bernard Le Mans France Details
Hopital Franco-Britannique - Fondation Cognacq-Jay Levallois-Perret France Details
CHRU Lille Lille France Details
Centre Léon Bérard Lyon France Details
Hôpital Privé Jean Mermoz Lyon France Details
Hôpital de la Timone Marseille France Details
ICM Val d'Aurelle Montpellier France Details
CHU Nantes- Hôtel Dieu Nantes France Details
Hôpital Saint Antoine Paris France Details
Institut Mutualiste Montsouris Paris France Details
CHU Bordeaux - Hôpital Haut Lévêque Pessac France Details
CHU Poitiers Poitiers France Details
Hôpital Robert Debré Reims France Details
CHU Toulouse - IUCT Rangueil -Larrey Toulouse France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field